Pashko S, Johnson D H
Center for Economic Studies in Medicine, a Division of Pracon Consulting Services, Reston, Virginia.
Pharmacoeconomics. 1992 Apr;1(4):293-7. doi: 10.2165/00019053-199201040-00006.
An economic analysis was conducted on a randomised multicentre study comparing the use of intravenous (IV) etoposide versus oral etoposide treatment regimens in patients with small cell lung cancer. 41 patients received cisplatin 100 mg/m 2 intravenously (IV) on study day 1 and etoposide 120 mg/m 2 IV on study days 1, 2, and 3 (IV regimen); and 42 patients received cisplatin 100 mg/m 2 IV and etoposide 120 mg/m 2 IV on study day 1 and 240 mg/m 2 orally (equivalent to 120 mg/m 2 IV) on study days 2 and 3 (oral regimen). The results of the study from which these data were extracted showed equal efficacy between groups. Based on a retrospective review of resource use in the clinical trial, patient healthcare costs were examined in the following areas: antineoplastic drugs, IV fluids, supplies used for chemotherapy administration, and chemotherapy administration procedure fees. The total cost per course of therapy was $US2002 for the IV regimen and $US1653 for the oral regimen. This represented a 17% savings for patients receiving the oral regimen.
对一项随机多中心研究进行了经济分析，该研究比较了小细胞肺癌患者静脉注射依托泊苷与口服依托泊苷治疗方案的疗效。41例患者在研究第1天静脉注射顺铂100mg/m²，在研究第1、2、3天静脉注射依托泊苷120mg/m²（静脉注射方案）；42例患者在研究第1天静脉注射顺铂100mg/m²和依托泊苷120mg/m²，在研究第2天和第3天口服240mg/m²（相当于静脉注射120mg/m²）（口服方案）。提取这些数据的研究结果显示两组疗效相当。基于对该临床试验资源使用情况的回顾性分析，对患者医疗费用在以下方面进行了检查：抗肿瘤药物、静脉输液、化疗给药用品以及化疗给药程序费用。静脉注射方案每疗程的总费用为2002美元，口服方案为1653美元。这表明接受口服方案的患者节省了17%的费用。
